MRNA
مرنةTechnical Analysis & Signals
Marnah stock is experiencing a downward trend with negative signals in technical analysis.
Technical Analysis
The stock shows negative signals with bearish divergence, indicating a continuation of the downtrend. The Relative Strength Index (RSI) at 38.8 suggests that the stock may be in oversold territory.
Support & Resistance Levels
The main support level is at 8.09 SAR, while resistance is at 8.45 SAR. The stock is expected to react to these levels in the upcoming sessions.
Volume Analysis
Trading volume may indicate weakness in momentum, as the downtrend coincides with declining volume. This could suggest a lack of interest from investors.
Fundamental Factors
The price-to-earnings (P/E) ratio is high at 817.0, indicating a high valuation for the stock. Additionally, the 0% dividend yield reflects a lack of profit distribution to shareholders.
Risk Factors
The stock faces downside risks due to the overall negative trend and technical indicators. General economic conditions in the Saudi market may impact the stock's performance.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. Investors are advised to monitor the stock's technical performance and make decisions based on personal analysis.
Automated analysis is based on historical data and technical indicators and may not reflect future market conditions.
Financial Fundamentals
Price Data
Price Chart - MRNA
4082Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Within BandTrend Strength (ADX)
Weak TrendFinancial Summary
Valuation
- Market Cap
- 583.57M
- P/E Ratio
- 817.00
- P/B Ratio
- 0.70
- EPS (Earnings/Share)
- 0.01
Profitability
- Revenue
- 136.30M
- Net Income
- 1.01M
- Return on Equity (ROE)
- 0.00%
- Shares Outstanding
- 71.43M
Balance Sheet
- Total Assets
- N/A
- Total Debt
- 569.62M
- Debt/Equity
- 0.68
- Free Float %
- +61.7%
Dividends & Margins
- Dividend Yield
- 0.00%
- Dividend/Share
- 0.00
- Book Value
- 11.67
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
5 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2025 | 218.48M +13.0% | 1.01M -96.9% | 1.44B +0.9% | 569.62M +4.9% | 0.01 -97.8% |
| 2024 | 193.41M +14.2% | 32.72M +5.6% | 1.43B +6.4% | 543.12M +17.1% | 0.46 +7.0% |
| 2023 | 169.42M +7.1% | 30.97M -31.2% | 1.34B +9.7% | 463.84M -25.8% | 0.43 -31.7% |
| 2022 | 158.11M | 44.98M | 1.22B | 625.04M | 0.63 |
| 2021 | — | — | — | — | — |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
MRNA appoints Salman Al-Asmari as Chairman, Naif Al Maiman Vice Chairman
MRNA Chairman Abdulrahman Al-Ghimlas resigns
Ex-MRNA MD Waleed Al-Ghamlas wins SAR 1.85M labor claim
MRNA delays Q1 2025 results due to auditor change
MRNA shareholders agree to file liability lawsuit against ex-MD
Highest-paid executives, board members of Saudi-listed firms in 2024
Financing firms’ credit portfolios grow 12% to SAR 85B in 2023
Financing firms’ credit portfolio up 11% to SAR 80.7 bln in H1 2023
News source: Argaam (argaam.com)
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-05-11
Risk Assessment
Risk Factors
Average True Range 2.3% of stock price
Trading volume near or above average
P/E ratio 817.0 — above average
Debt-to-equity ratio 0.68
ADX indicator at 16 — no clear direction
High volatility and financial pressures requiring careful monitoring
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is MRNA stock price today?
MRNA (4082) stock price today is 8.17 SAR, declining by -1.09% compared to the previous session close. The 52-week price range is between 8.09 SAR and 12.73 SAR.
2 What is MRNA stock valuation?
The automated analysis signal for MRNA is "Sell" with 65% confidence. The P/E ratio is 817.0. The P/B ratio is 0.70.
3 Is MRNA Shariah-compliant?
Yes, MRNA (4082) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are MRNA dividend distributions?
No dividend payment data is currently available for MRNA. The company may not distribute dividends or the data has not been updated yet.
5 What is MRNA weekly performance?
MRNA performance over different time periods: weekly change -3.88%, monthly -6.74%, and year-to-date -15.60%. The stock is currently trading with a volume of 140,287 shares.
6 What is the target level for MRNA?
According to automated analysis for MRNA: Short-term target (1-2 weeks): 8.00 SAR. Support level: 8.09 SAR. Resistance level: 8.45 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.